Sativex for the management of multiple sclerosis symptoms

Perras C

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
Perras C. Sativex for the management of multiple sclerosis symptoms. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4

Authors' objectives
The aim of this report is to review the available information on Sativex, a cannabis-based pharmaceutical product containing delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:1 ratio, delivered in an oromucosal (mouth) spray, approved as adjunctive treatment for neuropathic pain in patients with multiple sclerosis (MS) and being investigated for the management of other MS symptoms, such as spasticity.

Authors' conclusions
In some trials, THC:CBD spray significantly reduced neuropathic pain, spasticity, muscle spasms and sleep disturbances. The most common adverse events reported in trials were dizziness, sleepiness, fatigue, feeling of intoxication and a bad taste. Long-term safety and the potential for dependence, abuse, misuse and diversion are unknown.

Project page URL
https://www.ccohta.ca/

Indexing Status
Subject indexing assigned by CRD

MeSH
Cannabidiol; Costs and Cost Analysis; Multiple Sclerosis /drug therapy; Pain /drug therapy; Tetrahydrocannabinol

Language Published
English, French

Country of organisation
Canada

Address for correspondence
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392; Email: jills@ccohta.ca

AccessionNumber
32005001205

Date bibliographic record published
07/11/2005

Date abstract record published
07/11/2005